Salfeld JG - Search Results

1

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review.

Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tracey D, et al. Among authors: salfeld jg. Pharmacol Ther. 2008 Feb;117(2):244-79. doi: 10.1016/j.pharmthera.2007.10.001. Epub 2007 Oct 26. Pharmacol Ther. 2008. PMID: 18155297 Review.

2

Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor.

Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, Hanzatian DK, Salfeld J, Sasso EH. Kaymakcalan Z, et al. Clin Immunol. 2009 May;131(2):308-16. doi: 10.1016/j.clim.2009.01.002. Epub 2009 Feb 1. Clin Immunol. 2009. PMID: 19188093

3

Anti-Tumor Necrosis Factor With a Glyco-Engineered Fc-Region Has Increased Efficacy in Mice With Colitis.

Bloemendaal FM, Levin AD, Wildenberg ME, Koelink PJ, McRae BL, Salfeld J, Lum J, van der Neut Kolfschoten M, Claassens JW, Visser R, Bentlage A, D'Haens GRAM, Verbeek JS, Vidarsson G, van den Brink GR. Bloemendaal FM, et al. Gastroenterology. 2017 Nov;153(5):1351-1362.e4. doi: 10.1053/j.gastro.2017.07.021. Epub 2017 Jul 27. Gastroenterology. 2017. PMID: 28756234

4

Fc Receptor-mediated Effector Function Contributes to the Therapeutic Response of Anti-TNF Monoclonal Antibodies in a Mouse Model of Inflammatory Bowel Disease.

McRae BL, Levin AD, Wildenberg ME, Koelink PJ, Bousquet P, Mikaelian I, Sterman AS, Bryant S, D'Haens G, Kamath R, Salfeld J, van den Brink GR. McRae BL, et al. J Crohns Colitis. 2016 Jan;10(1):69-76. doi: 10.1093/ecco-jcc/jjv179. Epub 2015 Oct 1. J Crohns Colitis. 2016. PMID: 26429698

5

CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis.

Stuhlmüller B, Häupl T, Hernandez MM, Grützkau A, Kuban RJ, Tandon N, Voss JW, Salfeld J, Kinne RW, Burmester GR. Stuhlmüller B, et al. Clin Pharmacol Ther. 2010 Mar;87(3):311-21. doi: 10.1038/clpt.2009.244. Epub 2009 Dec 23. Clin Pharmacol Ther. 2010. PMID: 20032971

6

Isotype selection in antibody engineering.

Salfeld JG. Salfeld JG. Nat Biotechnol. 2007 Dec;25(12):1369-72. doi: 10.1038/nbt1207-1369. Nat Biotechnol. 2007. PMID: 18066027 Review. No abstract available.

7

Use of new biotechnology to design rational drugs against newly defined targets.

Salfeld JG. Salfeld JG. Best Pract Res Clin Rheumatol. 2004 Feb;18(1):81-95. doi: 10.1016/j.berh.2003.10.001. Best Pract Res Clin Rheumatol. 2004. PMID: 15123039 Review.

8

Overview on the use of therapeutic antibodies in drug discovery.

Roguska M, Kaymakcalan Z, Salfeld J. Roguska M, et al. Curr Protoc Pharmacol. 2005 Jan 1;Chapter 9:Unit 9.7. doi: 10.1002/0471141755.ph0907s27. Curr Protoc Pharmacol. 2005. PMID: 22294129

9

The biotechnology era: has the promise been fulfilled?

Salfeld JG. Salfeld JG. Expert Opin Drug Discov. 2007 Dec;2(12):1549-53. doi: 10.1517/17460441.2.12.1549. Expert Opin Drug Discov. 2007. PMID: 23488899

10

Expression of antibodies using single-open reading frame vector design and polyprotein processing from mammalian cells.

Kunes YZ, Gion WR, Fung E, Salfeld JG, Zhu RR, Sakorafas P, Carson GR. Kunes YZ, et al. Among authors: salfeld jg. Biotechnol Prog. 2009 May-Jun;25(3):735-44. doi: 10.1002/btpr.182. Biotechnol Prog. 2009. PMID: 19363814

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

12 results

Search Page